GlaxoSmithKline already partners with Vectura on respiratory therapies, but some say the British pharma giant could be looking to take the pair’s relationship one step further.
Glaxo is preparing a 175-pence-per-share bid for the Chippenham, U.K.-based company, sources told The Telegraph. That offer would value Vectura at close to £1.2 billion.
If GSK does strike, it’ll be taking advantage of Vectura’s 2017 share price drop. In May, the FDA turned down a generic of GlaxoSmithKline blockbuster Advair from Vectura and partner Hikma, and investors have continued to pressure the stock as they await a final verdict from the regulatory agency, due this quarter, the newspaper notes.
And last week’s investment strategy update didn’t sit particularly well with shareholders, either. In it, Vectura said it would increase its focus on lower-risk pipeline development opportunities and “cease” investment in “relatively higher risk, novel molecule, early stage programs,” instead looking for partnerships in that arena.
Glaxo knows what it would be getting itself into with a Vectura buy. The drugmaker licensed Vectura’s technology for products such as Breo and Anoro, and Vectura boasts some “smart inhaler” technology that GSK may be interested in, too, The Telegraph notes.
While CEO Emma Walmsley has made clear that reviving Glaxo’s pharma portfolio is a top priority,, right now all eyes are on the company’s consumer unit—at least when it comes to M&A. GSK is weighing a bid for Pfizer’s on-the-block OTC division, along with rivals including Reckitt Benckiser.
By Carly Helfand
Source: Fierce Pharma
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.